Michael Haller Email & Phone Number

San Diego, California, Us

San Diego, California, Us

• Provide strategic guidance and business plan optimization to successfully monetize Denovo’s retrospective biomarker technology through in-licensing and development of “failed” late-stage assets and collaborative biomarker analysis.• Led acquisition of two Phase 3 compounds (Oncology, CNS) from Eli Lilly.• Assist with partnering efforts worldwide targeting Big Pharma and other companies with failed late-stage assets• Previously also held the position of Chief Operating Officer

San Diego, California, Us

Baltimore, Md, Us

Provide guidance to JHU BME leadership to ensure the Department of Biomedical Engineering is the leader in engineering the future of medicine.

• Advise on marketing plans and materials for GlyTech’s proprietary technology for developing synthetic biologics.• Cultivate business development targets and ex-Japan partnering efforts• Assist with negotiations• Previously held the position of Vice President, Business Development

San Diego, Ca, Us

• Conducted out-licensing activities, including business development strategy and execution, leading to business offers for difficult-to-partner assets.• Created comprehensive process and tools for evaluating, tracking, and managing Ligand’s 70+ alliances, including forecasting economic implications of alliance events and managing relationships.• Completed strategic evaluations of potential acquisitions, expansion of Ligand’s drug delivery business into new markets, and indication expansion for a commercial partnered program

La Jolla, Ca, Us

• As member of Senior Management reporting to CEO, set company’s strategy, manage operations, and add responsibilities as necessary.• Led Anaphore’s partnerships, including Mitsubishi Tanabe Pharma Corporation ($345M deal) and additional collaborative projects.• Established and managed operations of Anaphore’s China site, including completion of all required activities to establish a Wholly Foreign-Owned Entity (WFOE) and creating and owning the associated budget.• Managed CMC scale-up activities to optimize and select best production host from among several mammalian and bacterial hosts, to ensure commercially-scalable manufacturing for Anaphore’s Atrimer® protein scaffold platform.• Led effort for identifying and securing VIP-accelerating assets.

San Diego, California, Us

Vice President of Alliance Management and Head of Drug Delivery Franchise (2009-2011)• Responsible for setting and executing Halozyme’s drug delivery platform strategy, including protecting existing partnerships and obtaining new partnerships through design and execution of commercial and technical activities. • Directed all alliances, including Roche Pharmaceuticals, Baxter BioScience, and Baxter Medication Delivery, to accomplish corporate goals, including program development, milestones, sales targets, external communications, and investor relations. • These drug delivery alliances raised over $103M in non-dilutive cash through 2Q2010, approximately 50% of Halozyme’s cumulative financing, and validated Halozyme’s drug delivery technology through advancement of three partnered programs (Herceptin® SC, MabThera® SC and HyQvia®) into pivotal trials within five years of deal signing. All three products are now approved for sale in major markets.Vice President of Alliance Management and Portfolio Development (2007-2009)• Responsible for leading all alliance and internal project teams, with all direct reports having advanced degrees (Ph.D. or equivalent). • Ensured effective portfolio prioritization to maximally deploy Halozyme’s resources through project planning and timely execution according to or faster than plan. • Led all aspects of the Chemophase program team, focused on bladder cancer, from preclinical through the end of Phase 2 clinical development.Senior Director of Corporate Development and Portfolio Management (2004-2006)• Responsible for all in-licensing activities, product portfolio analyses and decision-making, and strategic analyses for Halozyme. • Supported business development activities to out-license EnhanzeTM Technology, which culminated in signing of Roche ($612M deal) and Baxter BioScience ($47M deal). • In-licensed preclinical compound and co-led launch of HYLENEX® with Baxter Healthcare.

Us

Focused on healthcare, providing guidance to CEOs and senior management of biotechnology, branded pharmaceutical, generic pharmaceutical, medical device, and healthcare provider firms in a broad variety of functional areas, including strategy, sales and marketing operations, and research and development.

Ph.D., Biomedical Engineering

Ms, Chemical Engineering

Bs, Biomedical Engineering